Arcutis Biotherapeutics (ARQT) AGM 2026 summary

Opening remarks and agenda

• Meeting called to order with 86.46% of shares represented, confirming quorum.

• Chairperson introduced management, board members, independent auditor, and legal counsel.

• Agenda included voting on three proposals as outlined in the proxy statement.

Board and executive committee updates

• Three Class III directors, Patrick J. Heron, Neha Krishnamohan, and Todd Franklin Watanabe, stood for re-election to serve until 2029.

Shareholder proposals

• Election of three Class III directors for three-year terms.

• Ratification of Ernst & Young LLP as independent registered public accounting firm for 2026.

• Advisory, non-binding vote on executive compensation.